A Retrospective Review of the Frequency and Nature of Acute Hypersensitivity Reactions at a Medium-Sized Infusion Center: Comparison to Reported Values and Inconsistencies Found in Literature by DeMoor, Patricia A. et al.
Journal of Cancer 2011, 2 
 
 
http://www.jcancer.org 
153 
J Jo ou ur rn na al l   o of f   C Ca an nc ce er r   
2011; 2:153-164 
Research Paper 
A Retrospective Review of the Frequency and Nature of Acute Hypersensi-
tivity Reactions at a Medium-Sized Infusion Center: Comparison to Re-
ported Values and Inconsistencies Found in Literature 
Patricia A. DeMoor1*, Yuri Matusov2* , Colleen Kelly3, Shobha Kolan4, Linda Barnachea4, Lyudmila A. 
Bazhenova5  
1.  Infusion Center, University of California, San Diego Moores Comprehensive Cancer Center  
2.  Department of Clinical Investigations, University of California, San Diego Moores Comprehensive Cancer Center 
3.  Department of Biostatistics, University of California, San Diego Moores Comprehensive Cancer Center 
4.  Department of Pharmacy, University of California, San Diego Moores Comprehensive Cancer Center 
5.  Department of Medicine, Division of Hematology and Oncology, University of California, San Diego School of Medicine 
and Medical Center 
* These authors contributed equally to this work. 
 Corresponding author: Yuri Matusov, Clinical Trials Office, University of California, San Diego Moores Cancer Center, 
3855  Health  Sciences  Drive,  MC  0698,  La  Jolla,  California  92093-0698.  Tel:  (858)  246-0357;  Fax:  (858)  822-5380;  Email: 
matusov@ucsd.edu 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2010.11.04; Accepted: 2011.03.03; Published: 2011.03.10 
Abstract 
Purpose: To evaluate acute hypersensitivity reactions at the UCSD Moores Cancer Center in 
San Diego, compare our findings to those reported previously in the literature, and examine 
the effectiveness of the objective grading scale as represented by the Common Terminology 
Criteria for Adverse Events (CTCAE). 
Patients and Methods: Using the available pharmacy and electronic medical record data from 
2006-2010, we examined our reported hypersensitivity reactions (HSRs) using the CTCAE 
v.3.0 and v.4.0. A thorough literature review was also performed to compare our findings with 
those previously reported. 
Results: We found 222 cases of HSRs, of which 50% were due to immunotherapeutics. Most 
were grade 1 or 2 by any CTCAE criteria. The clinical presentation of HSRs varied between 
drug classes. Using different versions of grading schema led to inconsistencies in ~50% of all 
HSRs. Fifty-two percent of all cases not due to blood products were rechallenged on the same 
day. The reported literature HSR frequencies for each causative agent showed a striking 
variability, possibly indicating that previous studies used a wide variety of grading and re-
porting systems for adverse events. 
Conclusion: HSRs are common in clinical practice, and most are mild or moderate. There are 
inconsistencies in reporting HSRs between studies. The existence of several grading schema 
and subjective definitions of hypersensitivity could be contributing to poor clinical generali-
zability. Along with an improved system of reporting HSRs to minimize underreporting, a 
standard system of objectively assessing HSRs is necessary for purposes of research and 
clinical practice. 
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Introduction 
Acute  hypersensitivity  reactions  (HSRs)  are  a 
known source of great stress to patients, their families, 
nurses,  other  patients,  and  physicians1.  In  past  as-
sessments, 52% of a nursing staff has reported that 
infusion  reactions  are  draining  and  frightening  to 
them, and 42% of nurses feel that physicians do not 
adequately inform patients about the risk associated 
with an intravenous infusion2. Around 88% of outpa-
tient  and  62%  of  inpatient  nurses  consider  infusion 
reactions frightening to other patients, with the po-
tential  to  cause  anxiety  and  confusion2,3.  Since  the 
opening of the Rebecca and John Moores UCSD Can-
cer Center (MCC) in San Diego, California in 1978, it 
was  anecdotally  believed  that  no  patient  had  ever 
experienced a respiratory arrest-level HSR in the In-
fusion Center until May 2007, which prompted our 
clinical team to elucidate our adverse event profile, 
compare it to reports published previously, and re-
view our practices regarding intravenous infusion of 
drugs  with  increased  risk  of  hypersensitivity.  The 
development of a variety of assessment tools, of novel 
therapies, and of evolving premedication schema in 
the past decade has made standardization of assess-
ment  challenging;  this  has  resulted  in  substantial 
misrepresentation  of  HSR  incidence  and  severity, 
both to patients and providers. To improve care for 
patients receiving these therapies, and to improve the 
safety  and  efficacy  of  outpatient  administration  for 
these  therapies,  we  felt  it  necessary  to  evaluate  the 
HSR  environment;  specifically,  what  should  be  ad-
dressed  is  the  true  frequency  and  incidence  in  the 
modern setting, the factors which providers take into 
account when assessing and treating HSRs, and the 
scientific  soundness  of  certain  treatment  methods. 
Given the amount and variety of therapies adminis-
tered at our center, it was felt to be an appropriate 
environment for such an initial evaluation.  
Materials and Methods  
 The retrospective review was approved by the 
University of California, San Diego Institutional Re-
view Board. HSRs taking place from June 2006 until 
January 2010 in the MCC were reported by clinical 
staff as part of the Infusion Center Standard Operat-
ing Procedure using the electronic Quality Variance 
Reporting (eQVR, Incident Reporting 2.0, University 
of  California)  system,  a  web-based  event  tracking 
system  for  collecting  and  analyzing  data  regarding 
patient care service quality. During this time the MCC 
administered over 30,850 infusions to about 4,000 pa-
tients.  All  HSRs  reported  by  eQVR  were  reviewed 
twice, independently, by PAD and YM. Baseline data, 
including  patient  demographics,  history  of  known 
allergies,  premedications  administered  (and  the  ad-
herence  to  this  institution‟s  existing  standard  pre-
medication protocols), agent suspected of causing the 
HSR, signs and symptoms, reaction management, and 
the decision to same-day rechallenge were collected, 
using the PCIS (Siemens Invision Clinicals, Siemens 
Medical  Solutions,  Malvern,  PA)  and  Hyperspace 
Clinical  EMR  (Epic  Systems,  Verona,  WI)  electronic 
medical  record  system.  Since  the  eQVR  links  each 
HSR  to  a  unique  medical  record  number,  the  team 
verified  that  there  were  no  duplicate  HSR  reports. 
Each HSR was graded retrospectively (not at time of 
event)  using  three  separate  grading  systems  –  the 
Common  Terminology  Criteria  for  Adverse  Events 
(CTCAE)  version  3.0  Allergic  Reac-
tion/Hypersensitivity  (AR),  CTCAE  v.3.0  Cyto-
kine-Release  Syndrome/Acute  Infusion  Reaction 
(CRS), and CTCAE v.4.0 Infusion-Related Reaction87. 
Reaction attribution to an agent was ascertained from 
practitioners‟  notes  of  the  event  in  question.  ADRs 
were  analyzed  for  various  characteristics  using  Mi-
crosoft  Excel  2003  (Microsoft,  Redmond,  Washing-
ton). Total drug administration at the MCC was de-
termined by utilizing three pharmacy drug database 
systems (PCIS, Siemens, Epic) used during the time 
period. A thorough literature review of package in-
serts, prospective and retrospective studies, and an-
ecdotal case reports (dating from the time of the reg-
istrational clinical trials for each agent until 2010) was 
then  performed  in  the  interest  of  determining  HSR 
frequency and incidence at other locations. This was 
done during 2010 by performing searches of the com-
binations of the terms “adverse effect,” “hypersensi-
tivity,”  “adverse  reaction,”  “adverse  drug  reaction” 
with the names of therapeutic agents in PubMed and 
MedLine,  with  280  reports  found.  The  selected  100 
unique reports were in English with a primary focus 
on acute adverse effects of chemotherapeutic and bi-
otherapeutic agent or experiences with acute hyper-
sensitivity  events  in  oncology  outpatient  settings. 
These reports were analyzed for the method of HSR 
assessment, HSR frequency and incidence, changes in 
administration practice, differences in perceived and 
actual HSR risk on the part of patients and providers, 
pharmacological  HSR  mechanisms,  and,  where  ap-
plicable, impact on the institution.  
Statistical Analysis 
 Cohen‟s weighted kappa was calculated to as-
sess  the  consistency  between  CTCAE  v.3.0  AR  and 
CTCAE v.3.0 CRS, where large discrepancies between Journal of Cancer 2011, 2 
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HSR grades are weighted more heavily than similar 
grades.  The  weighted  kappa  statistic  was  assessed 
using the Landis and Koch scale (1977), which trans-
lates  the  numerical  score  into  categories  of  poor, 
slight, fair, moderate, substantial, or almost perfect. 
The  average  HSR  grades  were  compared  between 
subjects rechallenged and those that were not, overall 
and  by  drug  category,  using  the  Mantel-Haenszel 
chi-square test of a linear association.  
Results 
 We found a total of 222 documented HSRs in our 
Infusion  Center  from  June  2006  until  January  2010. 
The median age of female and male patients was 47 
and 69 years old, respectively; 59% of patients evalu-
ated were women (Table 1). Patients were evaluated 
for average exposure to the causative agent at the time 
of  the  reaction,  defined  as  the  number  of  previous 
times that a patient received the therapy plus the one 
causing  the  HSR.  Of  medications,  platinums  were 
most likely to cause an HSR with extensive exposure. 
In 12 cases, HSRs took place on secondary exposure to 
a  medication  (i.e.,  re-treatment  with  the  agent  fol-
lowing disease recurrence for patients who had been 
treated with it after the initial diagnosis). For those, 
the  average  exposure  to  the  agent  was  as  follows: 
platinums, 2.3; immunotherapy, 1; iron products, 1.  
 Approximately 60% of patients had no known 
allergies and 18% were known to have a single aller-
gen. There was no correlation between the number of 
known allergens and the likelihood of having a reac-
tion to a particular agent or drug class. 
Frequency and incidence of reactions 
 The  total  number  of  reactions  by  therapeutic 
agent, administrations of the HSR-causing agent, pa-
tients  receiving  the  agent  during  the  specified  time 
period, rate of HSRs per administration („administra-
tion  frequency‟)  and  per  patient  („incidence‟),  and 
values found in the literature are summarized in Ta-
ble  2.  When  compared  to  individual  agents,  ritux-
umab caused the majority of HSRs (27%), followed by 
paclitaxel (10%). It should be noted that all iron agents 
(responsible for 5.9% of all HSRs) were classified to-
gether;  because  of  the  low  HSR  incidence  to  iron 
agents,  they  were  not  separated  into  low-  and 
high-molecular weight preparations.  
   
 
 
 
Table 1. Patient demographics and prior allergy history. 
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Table 2. Total HSRs with drugs suspected of their causality, June 2006-January 2010. 
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Total administration of certain agents could not 
be  ascertained,  either  because  they  were  too  fre-
quently  used  (as  with  reactions  to  premedications), 
experimental with yet-unpublished data, or otherwise 
unavailable to the study team (as with blood prod-
ucts). Values reported in the literature are noted in 
terms of general HSR incidence and incidence of se-
vere HSR. Only the most common agents were eval-
uated in this literature review. 
  
 
Figure 1. HSR-causative agents, as a percentage of the total 
number of HSRs, separated by drug class, June 2006-January 
2010.  The  upper  chart  includes  blood  products.  ‘Other 
treatment’ comprises all agents with a single HSR case. The 
lower chart is a breakdown of causative agents within the 
class of immunotherapeutic agents. 
 
 
There were substantial differences between HSR 
administration  frequency  and  incidence  for  several 
common HSR-causing agents; specifically, rituxumab 
had  a  1.9%  admininistration  frequency  and  a  10% 
incidence,  paclitaxel  had  a  0.8%  administration  fre-
quency and a 4.4% incidence, and alemtuzumab had a 
2.2% administration frequency and 42.9% incidence at 
our center. 
 The most commonly-administered drug at our 
center,  of  available  data, was  intravenous  immuno-
globulin (given 3,717 times), followed by gemcitabine 
(given 3,249 times) and rituxumab (given 3,213 times). 
However, rituxumab was given to the greatest num-
ber of patients (n=600), followed by paclitaxel (n=520) 
and cisplatin (n=451).  
Figure  1  outlines  the  breakdown  of  causative 
agents  into  specific  drug  classes.  Immunotherapeu-
tics, as a class, accounted for half of the HSRs, with 
rituxumab accounting for 54% of the cases within the 
immunotherapeutic class. When blood products, ac-
counting for 33 cases, are excluded, HSRs to immu-
notherapeutics account for 58% of all HSRs, taxanes 
14%, platinum agents 13%, and iron products 7%. An 
investigational monoclonal antibody (still in clinical 
trials,  with  safety  data  unpublished)  was  felt  to  be 
responsible for 2 of the HSRs. 
Reaction Severity 
 All  sign,  symptom  and  rechallenge  data  re-
ported  is  provided  on  a  per-HSR  case,  rather  than 
per-patient, basis. Since only 8 patients experienced 
more than one HSR, the rates per HSR case should be 
similar to the rates per patient. The profile of the most 
commonly  reported  signs  and  symptoms  per  drug 
class is shown in Figure 2. The distribution of signs 
and symptoms reported at below 20% was more var-
ied. Patients experiencing HSRs to taxanes reported 
the following signs or symptoms in more than 50% of 
cases: thoracic symptoms (chest pain, tightness, and 
pressure  –  61.5%),  respiratory  symptoms  (dyspnea, 
wheezing, and desaturation  – 53.8%), and dermato-
logical symptoms (46.1%). For platinum agents, these 
were respiratory symptoms (68%) and dermatological 
symptoms  (64%).  In  regard  to  immunotherapeutic 
agents, blood products, and iron products, the most 
common  findings  were  chills  and  rigors  (46.4%), 
dermatological symptoms (36.4%), and both derma-
tological and respiratory symptoms (38.5%), respec-
tively. The treatment methods for HSRs to each drug 
class  were  very  similar,  utilizing  mainly  diphenhy-
dramine (>60% of all cases), and intravenous hydro-
cortisone and oxygen (>20% of cases each). There was 
no deviation from this instution‟s standard premedi-
cation protocol in the case of any HSR. 
 HSRs graded with the 3 different criteria of the 
CTCAE demonstrated an evident difference depend-
ing  on  which  criterion  of  the  CTCAE  v.3.0  (AR  or Journal of Cancer 2011, 2 
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CRS) was utilized (Figure 3). Using the CTCAE v.3.0 
CRS  and  CTCAE  v.4.0  Infusion-Related  Reaction 
schema led to identical grade values. The HSR grades 
were consistent across all schemas in approximately 
50% of cases, though this frequency was slightly low-
er among taxanes (34.6% consistency) and iron prod-
ucts (30.8% consistency). Overall, Cohen‟s weighted 
kappa  was  0.487,  a  value  representing  “moderate 
agreement”  by  Landis  and  Koch‟s  scale.  Weighted 
kappa was lowest for iron products (0.255) and tax-
anes (0.287), and highest for blood products (0.562). 
Figure  4  illustrates  both  the  relative  totals  of  each 
grade as well as the differences in these totals as a 
result of different grading systems. The majority of 
HSRs  were  moderate-to-severe  (CTCAE  grade  2-3), 
with two HSRs resulting in death (one to carboplatin 
and one to gemtuzumab). 
Rechallenge 
 There were 98 (52% of HSRs not due to blood 
products)  attempts  to  rechallenge  patients  on  the 
same day following HSR. Nearly all (n=92) were suc-
cessful. Only 3 HSRs due to blood products were fol-
lowed  by  rechallenge,  and  all  were  successful.  Im-
munotherapeutics were rechallenged most often (69% 
of all rechallenged agents), with generally good suc-
cess (only 5 cases could not be rechallenged success-
fully).  Regardless  of  the  grading  method  used,  the 
overall  HSR  grade  distribution  was  significantly 
lower for those reactions that were rechallenged than 
for those that were not (p-value<0.05). There was a 
larger difference in the HSR grade distributions be-
tween  these  groups  when  the  CTCAE  AR  grading 
system  was  used.  However,  when  restricted  to  im-
munotherapy reactions, the HSR grades distributions 
were  essentially  the  same  in  these  groups.  Twen-
ty-one  cases  were  rechallenged  following  reactions 
that were grade 3-4 by both criteria.  
 
 
 
 
Figure 2. Frequencies of the three most common signs and symptoms reported per drug class. Since each HSR may have 
presented with more than one symptom, the frequencies do not add to 100% in each class. Dermal symptoms include 
erythema, flushing, pruritis, and urticaria. Respiratory symptoms include dyspnea, wheezing, and desaturation. Thoracic 
symptoms include chest pain, tightness, and pressure (but do not include cardiac S&S). All reported S&S were those not 
present at baseline.  Journal of Cancer 2011, 2 
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Figure 3. Breakdown of HSRs, June 2006-January 2010, as graded by CTCAE v3.0 
 
 
 
Figure 4. Differences in breakdown of HSRs of a particular grade when using CTCAE v.3. Cytokine Release Syndrome / 
Acute Infusion Reaction (C.R.S.) and CTCAE v.3 Allergic Reaction / Hypersensitivity (A.R.). There were no grade 1 reactions 
as per CTCAE v.3 Acute Hypersensitivity / Infusion Reaction.  Journal of Cancer 2011, 2 
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Discussion 
 Severe HSRs are reported in ≤ 5% of all chemo-
therapy  infusions,  with  platinum  compounds  and 
taxanes  accounting  for  the  greatest  risk,  but  milder 
HSRs are certainly no rarity in any infusion center13. 
HSR  risk  is  quoted  by  physicians  when  presenting 
treatment  options  to their patient and is  utilized in 
appropriate  infusion  center  staffing,  so  there  is  no 
question that the study of HSRs is one which will re-
main relevant.  
 Our review of the literature, while covering only 
major agents, revealed that there are enormous dis-
parities in HSR risk not only between our data and 
published reports, but also among the reports them-
selves.  There  are  substantial  confounding  factors 
which  must  be  remembered  when  quoting  reaction 
risk, including inconsistencies in the CTCAE v.3.0, the 
most commonly-used HSR assessment tool in oncol-
ogy  today88.  The  terminology  currently  used  to  de-
scribe an HSR is by no means standard.  
 The  commonplace  term  „allergic  reaction‟  fell 
under criticism as scientifically inaccurate as early as 
197973.  An  allergy  –  that  is,  a  type  I,  IgE-mediated 
immune  response  –  is  facilitated  by  a  sensitization 
period  of  repeat  exposure  to  the  allergen.  HSRs  to 
carboplatin and oxaliplatin support this feature; the 
incidence  of  HSRs  per  patient  population  increases 
with the number of doses given and in cases of doc-
umented  occupational  exposure  to  platinum  salts. 
However,  a  longer  platinum-free  interval  between 
courses of carboplatin has been correlated to an in-
creased  incidence  of  HSR1,3,19,20,22-28,37,40,89.  The 
IgE-mediated mechanism is thus not wholly accurate, 
and has led researchers to question the validity of the 
reaction as an allergic one, to consider the possibility 
of  a  non-immunological  histamine  release,  and  to 
even view the nature of a HSR as idiosyncratic19,23.  
 Similarly, there is a lack of consensus regarding 
mechanisms of HSRs to monoclonal antibodies. Fre-
quent  initial-exposure  reactions  to  cetuximab, 
alemtuzumab, and rituxumab counter IgE-mediated 
hypersensitivity5,7,29; infliximab, however, is known to 
cause reactions after multiple rounds of therapy90,91.  
 There is a great deal of conviction, however, that 
taxane HSRs are non-IgE-mediated. These HSRs are 
most frequent at first or second exposure, are severe 
only during these administrations, nearly all patients 
rechallenged after the first administration are able to 
tolerate  subsequent  cycles,  and  they  are  dose-  and 
rate-dependent12,17,49,92.  Nonetheless,  the  majority  of 
studies reviewed here used the CTCAE AR grading 
criteria. 
 Today‟s premedication protocols do not always 
reflect those environments in  which  trials  were ini-
tially conducted. Many early cisplatin trials did not 
utilize  glucocorticoids  and  antihistamines,  as  is 
commonly  done  today9,58,59,61,62,64,68,69,73,  which  may 
account  for  the  decreased  incidence  in  more  recent 
studies.  There  are,  additionally,  documented  de-
creases  of  over  50%  in  HSR  incidence  (general  and 
severe)  in  trials  where  premedication  for  docetaxel 
and  paclitaxel  was  standard11,14-16,48,49,51,93-98.  Citation 
errors remain; as Weiss and colleagues have noted, 
citation  of  older  publications  with  a  different  pre-
medication protocol as references in modern reports 
has led to significant discrepancies. 
 In  clinical  trials,  investigators  continue  to  em-
ploy  a  wide  variety  of  grading  scales.  The  CTCAE 
itself  has  undergone  several  revisions  (v.4  released 
May 2009), but as late as 2003, teams have used early 
versions  of  the  CTCAE  for  assessing  severity  of 
HSRs81,82.  The  World  Health  Organization,  Eastern 
Cooperative Oncology Group, and Radiation Therapy 
Oncology Group sometimes use their own scales for 
grading allergic reactions. Furthermore, the majority 
of  trials  reviewed  here  used  a  subjective  variety  of 
terms to define a reaction; the definitions of each of 
these  terms,  where  provided,  infrequently  corre-
sponded to those in the CTCAE. Some studies graded 
each sign and symptom of a HSR separately using the 
CTCAE, rather than as general condition. At least one 
team has proposed a completely new, 3-grade, system 
for anaphylaxis whereas another has suggested elim-
ination of the anaphylaxis category altogether99-102.  
 The CTCAE v.3.0 itself poses another problem. 
In using AR and CRS scales, the same hypersensitivity 
reaction can be graded as moderate (grade 2), severe 
(grade 3), or life-threatening (grade 4); this was evi-
dent at our center. Moreover, the CTCAE v.3.0 indi-
cates parenteral rescue medications in grade >3 aller-
gic  reactions,  whereas  these  are  given  at  the  first, 
mildest, sign of a HSR in most infusion centers88, in-
cluding  ours.  Many  inconsistencies  have  been  re-
moved  in  the  CTCAE  v.4.0,  which  provides  nearly 
identical  gradations  of  allergic  reactions  and  infu-
sion-related  reactions,  and  features  a  new  category, 
anaphylaxis, which is consistent with the other rele-
vant categories.  
 Some reports provide a risk of HSR per number 
of infusions and others per number of patients, which 
adds an additional layer of inconsistency. This is not 
irrelevant; as our data indicates, the difference in re-
ported percentages can be hundredfold (Table 2 sub-
selects  for  those  reports  which  provided  incidence 
figures in the same manner as do we). Often, the cal-
culation method is not specified in published reports, 
establishing  a  potential  for  misquoting.  Our  review Journal of Cancer 2011, 2 
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showed at least three published articles citing previ-
ous research erroneously. 
 The  importance  of  consistent  grading  is  not 
trivial; reported differences in percentages can lead to 
misconceptions  about  HSRs  and  their  management, 
misinformation given to patients as they prepare to 
initiate treatment, and inappropriate staffing in infu-
sion centers. Only with a variety of prospective eval-
uations  of  therapies  using  a  standardized  grading 
scheme will we understand the true reaction frequen-
cies, an exact profile, and an evidence-based method 
for the decision to rechallenge.  
 While the most obvious use of a standard grad-
ing system is in data reporting for clinical research, 
the grade for a HSR can have bearing on the physi-
cian‟s  clinical  judgment.  Another  past  literature  re-
view  indicated  that  patients  who  had  a 
mild-to-moderate (grade 1-2) reaction on first expo-
sure are likely to tolerate rechallenge with a drug; this 
is contraindicated in patients having a grade 3-4 reac-
tion13.  However,  some  reports  asserted  that 
mild-to-moderate reactions to monoclonal antibodies 
only require a decrease of rate, rather than cessation 
altogether103. Immediate re-treatment, particularly on 
the same day with the same preparation, is especially 
important for outpatient treatment centers and their 
patients.  If  performed  properly,  it  can  result  in  the 
minimizing of treatment time and costs without ad-
versely affecting patient safety12.  
 This topic should also continue to be explored 
for  educational  purposes.  At  our  institution,  the 
full-time  staffing  of  the  Infusion  Center  with  dedi-
cated Physician Assistants experienced in the medical 
management  of  patients  experiencing  HSRs  has  re-
sulted in high rechallenge success rates and compre-
hensive  management  of  HSRs.  However,  we  found 
that the likelihood of the decision to rechallenge tax-
anes (a drug class with an unclear rechallenge indica-
tion)  increased  over  time,  with  no  similar  trend  in 
average  grade  of  the  reaction;  coincidentally,  the 
timeline  of  this  study  paralleled  the  initiation  of  a 
mid-level  practitioner  in  the  Infusion  Center.  This 
suggests that the deciding practitioner‟s knowledge of 
HSR management increases with time and is the key 
factor in making such a decision. 
 Finally,  the  study  of  HSR  mechanism  remains 
significant.  Although  IgE-mediated  and 
non-IgE-mediated reactions can be similar in clinical 
presentation,  they  are  vastly  disparate  in  mode  of 
development,  and  this  may  have  bearing  on  the 
pharmacological  interaction  of  rescue  medication90. 
Whether the mechanism of a reaction is relevant to 
clinical management remains under debate19. Specif-
ically,  one  report  pointed  out  that  treatment  of  a 
docetaxel  HSR  with  antihistamines  may  be  detri-
mental, as doing so inhibits cytochrome P450, which 
is responsible for docetaxel elimination49. Since many 
sites,  including  ours,  have  a  standing  protocol  for 
HSRs which includes antihistamines, an intravenous 
steroid, and possibly epinephrine, it is worthwhile to 
extend research in this area13,103. 
 In this study, HSR frequency and incidence was 
based solely on eQVR reporting, and there is a strong 
suspicion of underreporting or erroneous reporting of 
HSR frequency by eQVR; thus, there may be an un-
derestimation  of  true  reaction  frequency  and  inci-
dence (particularly among milder HSRs). In addition, 
this  study  was  a  retrospective  analysis  of  a  sin-
gle-center experience at an academic medical center; 
thus, extrapolation of the findings to other institutions 
must  be  done  with  care.  We  have  implemented  a 
comprehensive,  prospective,  multi-year  study  of 
HSRs at the MCC Infusion Center which bypasses use 
of  the  eQVR  system;  however,  continued  study  of 
HSRs at other institutions is necessary to validate the 
conclusions. 
Conclusion 
 The findings presented here indicate an inade-
quacy in the systematic reporting of acute hypersen-
sitivity reactions to non-oral medications. HSR inci-
dence tends to vary widely between reports, and thus 
the incidence and characteristics at MCC tend to re-
flect some, while strongly conflicting with others. A 
variety of CTCAE criteria and interpretations, differ-
ence  in  reporting  rates  as  administration  frequency 
versus incidence, an evolution of premedication, and 
citation errors all contribute to this issue. Since a mul-
titude of clinical decisions is based upon the conclu-
sions of reported literature, it is necessary to devise or 
formally adopt a system used universally for report-
ing HSRs. Finally, modern word processing software 
should be utilized to minimize referencing errors. The 
findings must be validated in larger, multi-center set-
tings with special emphasis on preventing underre-
porting or erroneous reporting. 
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